News
The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.
Eton Pharmaceuticals (ETON) stock gains as the FDA approved Khindivi its oral hydrocortisone solution for children with adrenocortical insufficiency. Read more here.
2d
Pharmaceutical Technology on MSNFDA approves Eton’s application for hydrocortisone oral solutionEton Pharmaceuticals’ new drug application (NDA) for Khindivi, an oral solution of hydrocortisone, has received US Food and ...
2d
InvestorsHub on MSNEton Pharmaceuticals Gains on FDA Green Light for Pediatric Drug KHINDIVIShares of Eton Pharmaceuticals Inc (NASDAQ:ETON) saw a 3.3% boost in premarket trading after the company announced U.S. Food ...
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) expects to launch KHINDIVI commercially the week of June 2, with combined peak sales ...
Read this article to find out why and how steroids such as dexamethasone are used – and withdrawn – in palliative care.
Oral submucous fibrosis (OSF) is a chronic condition commonly affecting the oral mucosa, causing an excessive buildup of collagen that disrupts tissue function and increases the risk of cancer.
Egg Beaters and Bob Evans liquid egg substitutes are impacted by the recall. Over 212,000 pounds of liquid egg products are being recalled due to the potential presence of cleaning solution.
Background Short-course oral corticosteroids are routinely used to treat acute asthma and croup. We evaluated their tolerability and palatability in Saudi Arabian (SA) and UK children. Methods ...
VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid ® (sacrosidase) Oral Solution has been shown to be ...
2 Side-effect profiles continue to emerge as ICIs become more widely used in oncology practice. Oral immune-related adverse events (irAEs) comprise a variety of lesions, including (1) dry mouth ...
Liporaxel oral solution showed non-inferiority in PFS and superiority in OS compared to IV Liporaxel in advanced gastric cancer patients. The phase 3 trial involved 536 patients, with a median OS of 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results